Inhibition of MXR Transport by Acridine Derivatives
Description of Invention:
The invention relates to a new use for a compound, an acridine derivative, as an inhibitor of multidrug resistance in cancer cells. Specifically, the inventors have shown that the compound modulates the transport of compounds from mitoxantrone-resistant (MXR) cells wherein the cells overexpress an MXR gene. The MXR gene is also known by the following designations: BCRP, ABCP, and ABCG2.
Inventors:
Susan Bates and Robert Robey (NCI)
Patent Status:
DHHS Reference No. E-258-1999/0 --
U.S. Patent No. 6,521,635 issued 18 Feb 2003
Portfolios: Cancer
Cancer -Therapeutics-Conventional Chemotherapy-Other Cancer -Therapeutics
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
